FDA Drug Approvals for Cancer in 2014
This slide show highlights the 2014 FDA approvals of cancer treatments, which included therapies for melanoma and lung, gastric, ovarian, and cervical cancers, as well as various hematologic malignancies.
On January 10, 2014, the US Food and Drug Administration (FDA) granted accelerated approval to the combination of trametinib (Mekinist) and dabrafenib (Tafinlar) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Recent Videos
The Evolution of EGFR-Mutated Advanced NSCLC Treatment: Present Considerations and Future Treatment Options
FDA Approvals for Multiple Myeloma
Treatment Approaches in Multiple Myeloma
MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data (Part 2)
MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data
Talquetamab in R/R MM: Managing GPRC5D-direced AEs, Prophylaxis, and New Safety Signals
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
Safety Updates and Concluding Thoughts From Extended Follow-Up of MonumenTAL-1
MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
Related Content
Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025Article
